Integrum Hires Prosthetics Industry Veteran to Lead U.S. Market Efforts

Share Article

Kurt Collier, Certified Prosthetist, has joined Integrum as VP of Prosthetics, bringing to the company a wealth of knowledge and support for bone anchored prosthetics efforts in the U.S.

Kurt Collier, Certified Prosthetist

“I have never been associated with a technology that so significantly improves the quality of life for amputees as this does."

This week in Las Vegas Integrum will exhibit and support the scientific sessions of the American Orthotic and Prosthetic Association (AOPA) 2017 World Congress. Integrum's OPRA™Implant System technology is commercially available in the U.S. and will be demonstrated at AOPA. At this appropriate venue Integrum will introduce the newest member of its team, industry veteran Kurt Collier, CP.

Integrum is pleased to announce that as of September 1st Kurt Collier has joined the company as Vice President of Prosthetics and will be responsible for introducing and creating a strong market awareness of Integrum’s OPRA™Implant System. A significant portion of Mr. Collier’s work over his near 30 years within the prosthetics industry has successfully involved bringing advanced prosthetic technology directly to clinicians through clinical education. He has also worked on facilitating and accelerating access to these advances within the amputee populations. “We believe Kurt’s unique skill set as a clinician, manufacturer, educator and an amputee make him a natural fit for the needs of the company,” states Jonas Bergman, Integrum CEO.

“I have never been associated with a technology that so significantly improves the quality of life for amputees as this does. I could not be more excited and honored to have the opportunity to help introduce the OPRA™Implant System to the prosthetists and amputees of the U.S.,” remarked Kurt Collier, the latest member of the growing Integrum team.

During the upcoming AOPA World Congress in Las Vegas September 6-9th Integrum will be present in the exhibit hall showcasing it’s products available in the U.S.. As part of the scientific program at AOPA Dr. Richard O’Donnell, Co-Director of the International Center for Osseointegration Research, Education and Surgery (iCORES), Department of Orthopedics, University of California San Francisco will present on early U.S. experience with the OPRA™ Implant System during a symposium on “Advancements in Osseointegration Technology for Amputees,” Friday afternoon, September 8th at 1:30pm. Dr. Rickard Brånemark, Co-Director of iCORES, Department of Orthopedics, University of California San Francisco will also present an overview of his more than 30 years work in the field of osseointegration during the same scientific program on Friday afternoon.

The OPRA™Implant System is the only FDA-approved, Bone Anchored Prosthetic solution available in the United States. OPRA™ consists of an anchorage element (fixture) and a skin penetrating device (abutment). The fixture is surgically inserted into the femur and after a healing time of six months the abutment is connected to the fixture. The prosthetic leg is then attached directly to the abutment via the OPRA™ Axor™, a prosthetic connection and safety device.

About Integrum

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden with a U.S. subsidiary in San Francisco, CA. Since 1990 osseointegration, the science behind the OPRA™Implant System, has been helping individuals with amputations towards an improved quality of life. A thorough surgical experience gained over two decades has lead to development of Integrum’s system for bone-anchored prosthetics – a beneficial alternative to the traditionally used socket prosthesis. Integrum is the scientific and thought leader in this area with patients from all parts of the world treated in 12 clinical centers with over 400 surgeries. Integrum’s OPRA™Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2015 for use in the U.S. under a Humanitarian Use Device (HUD) designation which was reviewed through the Humanitarian Device Exemption (HDE) pathway. The OPRA™ Implant System is the only FDA approved technology for bone anchored prosthetics available in the U.S.. More information on the company and its innovative solutions for amputees can be found at

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mrs. Anna-Tove Branemark, US CEO
Visit website